bioMérieux – Second-Quarter 2016 Business Review
Ximedica acquires Accel Biotech; Creates an Enhanced Offering for Life Science and Biomedical Instrument Product Development and Manufacturing Solutions
bioMérieux enlarges its pathogen identification capability on VITEK® MS
bioMerieux Receives FDA Clearance for Expanded Use of VIDAS® B.R.A.H.M.S PCT™ Test for Managing Sepsis Patients with Elevated Risk of Mortality
Global Companion Diagnostics Strategic Business Report 2016 - Analysis & Forecasts 2015-2022 - Research and Markets
Firm has a promising strategy of combining expertise in both areas to generate a growing personalized medicine pipeline.
Continued technology advancements and market expansion support Illumina's narrow moat.